Support teaching, research, and patient care.
Molecular imaging in oncologyPeripheral Nerve ImagingCellular imaging of musculoskeletal inflammatory diseasesKinematic musculoskeletal imagingMagnetic resonance imaging of hepatic disorders
Optimal Timing of BR55 CEUS of the Ovaries Not Recruiting
This is an exploratory, single center, open label, prospective study of BR55 to determine the optimal phase of the menstrual cycle for performing BR55 contrast-enhanced ultrasonography (CEUS) of the target ovary in premenopausal women scheduled to undergo preventative surgery because of high familial/hereditary or genetic risk for ovarian cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Amelie Lutz, MD, 650-498-2911.
View full details
BR55 in Characterization of Ovarian Lesions Not Recruiting
This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Aya Kamaya, 650-723-8463.
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases Not Recruiting
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases
Stanford is currently not accepting patients for this trial. For more information, please contact Risa Jiron, 650-736-1598.
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer Not Recruiting
Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results
Stanford is currently not accepting patients for this trial. For more information, please contact Phuong Pham, 650-725-9810.
Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer Not Recruiting
This pilot clinical trial studies how well photoacoustic imaging works in detecting ovarian or fallopian tube cancer. Photoacoustic imaging is an imaging method that uses lasers to light up tissue, and then converts the light information into ultrasound images. Photoacoustic imaging can provide images of the structure of tissues, as well as their function and the levels of molecules, such as the flow of blood in blood vessels and the level of oxygen in the blood. Photoacoustic imaging may help doctors determine whether a mass is benign (non-cancerous) or cancerous based on the molecular differences between cancer and normal tissue. It may be more accurate and less expensive than other imaging methods, and does not expose patients to radiation.
Stanford is currently not accepting patients for this trial. For more information, please contact Sri-Rajasekhar Kothapalli, .
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy Not Recruiting
Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.
Stanford is currently not accepting patients for this trial. For more information, please contact Andrei Iagaru, 650-736-2859.
